公开(公告)号：US09382318B2

公开(公告)日：2016-07-05

申请号：US13897096

申请日：2013-05-17

Applicant: Amgen Inc.

Inventor： Dirk E. Smith ,  Ian Foltz ,  Chadwick T. King ,  Ai Ching Lim ,  Rutilio Clark ,  Michael R. Comeau ,  Randal R. Ketchem ,  Donghui Shi ,  Xiaoshan Min ,  Zhulun Wang

IPC: C07K16/24 ,  C12N15/11 ,  C07K16/28 ,  A61K39/00

CPC classification number: C07K16/2866 ,  A61K2039/505 ,  C07K16/244 ,  C07K2317/21 ,  C07K2317/33 ,  C07K2317/34 ,  C07K2317/51 ,  C07K2317/515 ,  C07K2317/56 ,  C07K2317/565 ,  C07K2317/76 ,  C07K2317/92 ,  C12N15/11

Abstract: Described herein are compositions and methods related to antigen binding proteins that bind to human ST2, including antibodies. In particular embodiments, the disclosure provides fully human anti-ST2 antibodies and deriviatives and variants thereof. Further provided are nucleic acids encoding such antibodies and antibody fragments, variants, and derivatives. Also, provided are methods of making and using such antibodies including methods of treating and preventing autoimmune and inflammatory disorders.

Abstract translation: 本文描述的是与抗原结合蛋白相关的组合物和方法，其结合人ST2，包括抗体。 在具体实施方案中，本公开提供完全人抗-ST2抗体及其衍生物及其变体。 还提供了编码这种抗体和抗体片段，变体和衍生物的核酸。 此外，提供制备和使用这些抗体的方法，包括治疗和预防自身免疫性和炎症性疾病的方法。

公开(公告)号：US11518808B2

公开(公告)日：2022-12-06

申请号：US16245733

申请日：2019-01-11

Applicant: AMGEN INC.

Inventor： Khaled M. K. Z. Ali ,  Neeraj Jagdish Agrawal ,  Gunasekaran Kannan ,  Ian Foltz ,  Zhulun Wang ,  Daren Bates ,  Marissa Mock ,  Shunsuke Takenaka

IPC: C07K16/28 ,  A61P35/00 ,  A61K39/395 ,  C07K16/06 ,  C12N15/85

Abstract: Provided herein are PD-1 antigen-binding proteins and related nucleic acids, vectors, host cells, kits and pharmaceutical compositions. Methods of making PD-1 antigen-binding proteins and methods of treating a subject are further provided.

公开(公告)号：US11059895B2

公开(公告)日：2021-07-13

申请号：US16242278

申请日：2019-01-08

Applicant: Amgen Inc.

Inventor： Dirk E. Smith ,  Ian Foltz ,  Chadwick T. King ,  Ai Ching Lim ,  Rutilio Clark ,  Michael R. Comeau ,  Randal R. Ketchem ,  Donghui Shi ,  Xiaoshan Min ,  Zhulun Wang

IPC: C07K16/28 ,  C07K16/24 ,  A61K39/00 ,  C12N15/11

Abstract: Described herein are compositions and methods related to antigen binding proteins that bind to human ST2, including antibodies. In particular embodiments, the disclosure provides fully human anti-ST2 antibodies and derivatives and variants thereof. Further provided are nucleic acids encoding such antibodies and antibody fragments, variants, and derivatives. Also, provided are methods of making and using such antibodies including methods of treating and preventing autoimmune and inflammatory disorders.

公开(公告)号：US20210054069A1

公开(公告)日：2021-02-25

申请号：US16500378

申请日：2018-04-20

Applicant: AMGEN INC.

Inventor： Ian Foltz ,  Shilpa Sambashivan ,  Irwin Chen ,  Susie Miki Harris ,  Dora Toledo Warshaviak ,  Ian Driver ,  Daniel Lu

IPC: C07K16/28 ,  A61P25/28

Abstract: The present invention relates to antigen binding proteins, such as monoclonal antibodies, that specifically bind to and activate human triggering receptor expressed on myeloid cells-2 (TREM2) and pharmaceutical compositions comprising such antigen binding proteins. The agonist antigen binding proteins (e.g. antibodies) of the invention are capable of activating TREM2/DAP12 signaling in myeloid cells in the absence of Fc-mediated cross-linking of the antigen binding proteins. Methods of treating or preventing conditions associated with TREM2 loss of function, such as Alzheimer's disease and multiple sclerosis, using the antigen binding proteins are also described.

公开(公告)号：US20190046611A1

公开(公告)日：2019-02-14

申请号：US16054035

申请日：2018-08-03

Applicant: AMGEN INC.

Inventor： Khaled M.K.Z. Ali ,  Neeraj Jagdish Agrawal ,  Gunasekaran Kannan ,  Ian Foltz ,  Zhulun Wang ,  Darren Bates ,  Marissa Mock ,  Shunsuke Takenaka

IPC: A61K38/20 ,  A61P35/00 ,  C12N15/63 ,  C07K16/28

Abstract: Provided herein are IL-21 muteins and fusion proteins comprising the same for use in methods of treating a disease. Related conjugates, nucleic acids, vectors, host cells, pharmaceutical compositions and kits are also provided herein. Methods of making the IL-21 muteins and fusion proteins comprising the same, as well as methods of treating a subject in need thereof, are provided by the present disclosure. Further provided are PD-1 antigen-binding proteins.